528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Effective January 1, 2025, UDR promoted Mike Lacy from Senior Vice President of Operations to Chief Operating Officer and added the Chief Investment Officer role to CFO Joe Fisher's existing President and CFO titles. UDR will also start a search for a new Chief Financial Officer, and Fisher will give up that role once a successor is hired. The filing reports no financial results, and the changes affect shareholders mainly through who runs operations, investments and finance.
Mike Lacy, 43, appointed Chief Operating Officer effective January 1, 2025; he had been Senior Vice President - Operations since January 2019 and joined UDR in November 2006
Joseph D. Fisher appointed Chief Investment Officer effective January 1, 2025, while retaining his roles as President and Chief Financial Officer
UDR will begin an executive search for a new Chief Financial Officer; Fisher will relinquish the CFO role upon that hire
The company has not entered into any new compensation arrangements with Lacy in connection with his appointment
ADMA Biologics appointed Eduardo Rene Salas to its Board of Directors as a Class I director, effective December 30, 2024, with a term ending at the 2026 annual meeting. Salas has financial executive and audit experience, including former CFO of Wellstat Therapeutics and a 2002 to 2019 audit partner role at Ernst & Young. The filing describes this as a board appointment with standard non-employee director compensation, including an initial grant of options to purchase 20,011 shares.
Eduardo Rene Salas appointed to Board on December 30, 2024 as a Class I director
Term expires at the Company's 2026 annual meeting of stockholders
Served as CFO of Wellstat Therapeutics, LLC from 2020 to 2022
Initial grant of options to purchase 20,011 shares of common stock upon joining the Board
Gentex Corporation said Neil Boehm, its Chief Technology Officer, was appointed Chief Operations Officer effective January 1, 2025, while continuing as CTO. The company said the move is designed to better align business operations with its innovation and product strategies.
Neil Boehm appointed Chief Operations Officer, effective January 1, 2025, and will continue as CTO
Boehm has worked at Gentex since 2001 and has been CTO since 2018
Boehm has no written employment agreement and is an at-will employee; no family relationships with any director or executive officer
Filing includes News Release dated January 2, 2025 (Exhibit 99.1)
H.B. Fuller preliminarily expects fiscal 2024 adjusted EBITDA of about $594 million, below its prior guidance of $610 million to $620 million given on September 25, 2024. The company cited weaker fourth-quarter demand, delayed orders, and higher raw material costs, and said the figures are unaudited and subject to change.
Preliminary fiscal 2024 net revenue of about $3.57 billion, adjusted diluted EPS of about $3.84, and adjusted EBITDA of about $594 million
Prior adjusted EBITDA guidance was $610 million to $620 million, communicated September 25, 2024
Expected cash flow from operations of about $300 million for the year
Full fiscal 2024 results are scheduled for release after the market close on January 15, 2025, with a conference call on January 16, 2025
Avery Dennison disclosed that Martha N. Sullivan, a 12-year member of its Board of Directors, resigned effective December 31, 2024, to pursue new professional opportunities. The company said her resignation was not the result of any disagreement with the company on its operations, policies or practices.
Martha N. Sullivan notified the company of her resignation on December 27, 2024.
Her board resignation took effect December 31, 2024, after 12 years of service.
The filing states the resignation was not due to any disagreement with the company.
The 8-K gives no replacement director and includes no financial results.
Tutor Perini appointed its President, Gary Smalley, as Chief Executive Officer effective January 1, 2025, succeeding Ronald N. Tutor, who became Executive Chairman of the Board. Smalley also joined the Board, which expanded from nine to ten members. The change follows a succession plan the company first announced in November 2023, and the filing contains no financial results.
Gary G. Smalley became CEO effective January 1, 2025, after serving as President since November 2023.
Ronald N. Tutor moved to Executive Chairman, a role the release says he will hold through 2026.
The Board increased from nine to ten members to seat Smalley, who plans to stand for election at the 2025 Annual Meeting.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.